Explore every episode of the podcast JAMA Oncology Author Interviews
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Metastatic Recurrence Among Adolescents and Young Adults With Cancer | 26 Nov 2025 | 00:11:52 | |
Interview with Ann Brunson, MS, and Theresa H. M. Keegan, PhD, MS, authors of Metastatic Recurrence Among Adolescents and Young Adults With Cancer. Hosted by Vivek Subbiah, MD. | |||
| Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality | 30 Oct 2025 | 00:12:29 | |
Interview with Yiwen Zhang, PhD, and Edward L. Giovannucci, MD, ScD, authors of Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality. Hosted by Vivek Subbiah, MD. | |||
| Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer | 18 Sep 2025 | 00:13:26 | |
Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD. | |||
| Proportional Sedation for Persistent Agitated Delirium in Palliative Care | 31 Jul 2025 | 00:17:43 | |
Interview with David Hui, MD, and Eduardo Bruera, MD, authors of Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. | |||
| New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance | 29 May 2025 | 00:18:54 | |
Interview with Thorir Einarsson Long, MD, PhD, and Ola Landgren, MD, PhD, authors of New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. Hosted by Vivek Subbiah, MD. | |||
| Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury | 24 Apr 2025 | 00:12:23 | |
Interview with Shruti Gupta, MD, MPH, author of Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. Hosted by Vivek Subbiah, MD. | |||
| Accelerated Aging in Survivors of Childhood Cancer | 20 Mar 2025 | 00:19:19 | |
Interview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD. | |||
| Academic-Community Partnership and Deaths in Promyelocytic Leukemia | 27 Feb 2025 | 00:18:46 | |
Interview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD. | |||
| Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy | 30 Jan 2025 | 00:11:55 | |
Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD. | |||
| Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020 | 05 Dec 2024 | 00:16:08 | |
Interview with Katrina A. B. Goddard, PhD, author of Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. Hosted by Vivek Subbiah, MD. | |||
| Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib | 21 Nov 2024 | 00:18:46 | |
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. | |||
| Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma | 24 Oct 2024 | 00:20:41 | |
Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. | |||
| Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer | 05 Sep 2024 | 00:17:15 | |
Interview with Eileen M. O'Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD. | |||
| Identification of Immune Checkpoint Inhibitor–Induced Diabetes | 29 Aug 2024 | 00:14:36 | |
Interview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD. | |||
| Neoadjuvant Exercise Therapy in Prostate Cancer | 18 Jul 2024 | 00:19:01 | |
Interview with Lee W. Jones, PhD, author of Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial. Hosted by Vivek Subbiah, MD. | |||
| Endometrial Thickness as Diagnostic Triage for Endometrial Cancer in Black Individuals | 27 Jun 2024 | 00:15:04 | |
Interview with Kemi M. Doll, MD, MSCR, author of Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals. Hosted by Vivek Subbiah, MD. | |||
| T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy | 18 Apr 2024 | 00:19:57 | |
Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD. | |||
| Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time | 21 Mar 2024 | 00:25:53 | |
Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD. | |||
| Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer | 29 Feb 2024 | 00:14:26 | |
Interview with José P. Leone, MD, author of Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. Hosted by Nora L. (Mary) Disis, MD. | |||
| Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US | 04 Jan 2024 | 00:17:31 | |
Interview with Sajid A. Khan, MD, author of Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. Hosted by Mary L. (Nora) Disis, MD. | |||
| Atezolizumab in Combination With Carboplatin in Metastatic TNBC | 14 Dec 2023 | 00:18:18 | |
Interview with Jennifer A. Pietenpol, PhD, Brian D. Lehmann, PhD, and Vandana G. Abramson, MD, authors of Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. Hosted by Mary L. (Nora) Disis, MD. | |||
| Shorter-Course Radiotherapy for Prostate Cancer | 05 Oct 2023 | 00:15:14 | |
Interview with Daniel E. Spratt, MD, author of Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer. Hosted by Jack West, MD. | |||
| Sentinel Lymph Node Biopsy vs No Axillary Procedure in Small Node-Negative Breast Cancer | 21 Sep 2023 | 00:19:02 | |
Interview with Oreste Davide Gentilini, MD, author of Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. Hosted by Jack West, MD. | |||
| A Geospatial Analysis of Disparities in Access to Oncofertility Services | 10 Aug 2023 | 00:23:12 | |
Interview with Kara N. Goldman, MD, author of A Geospatial Analysis of Disparities in Access to Oncofertility Services. Hosted by Jack West, MD. | |||
| Integrated Clinical-Molecular Classification of Colorectal Liver Metastases | 20 Jul 2023 | 00:16:29 | |
Interview with Sean P. Pitroda, MD, author of Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. Hosted by Jack West, MD. | |||
| US Cancer Mortality Trends Among Hispanic Populations From 1999 to 2020 | 29 Jun 2023 | 00:17:16 | |
Interview with Sophia C. Kamran, MD, author of US Cancer Mortality Trends Among Hispanic Populations From 1999 to 2020. Hosted by Jack West, MD. | |||
| Oncolytic Viral Immunochemotherapy in Patients With Ovarian Cancer | 25 May 2023 | 00:15:07 | |
Interview with Robert W. Holloway, MD, and Sarfraz Ahmad, PhD, authors of Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. Hosted by Jack West, MD. | |||
| Radiosurgery of Spine Metastasis—NRG/RTOG 0631 RCT Final Results | 20 Apr 2023 | 00:14:15 | |
Interview with Samuel Ryu, MD, author of Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical Trial. Hosted by Jack West, MD. | |||
| Pathologic Complete Response and Clinical Outcomes in Soft Tissue Sarcoma | 30 Mar 2023 | 00:14:03 | |
Interview with Dian Wang, MD, author of Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. Hosted by Jack West, MD. | |||
| Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma | 16 Feb 2023 | 00:16:40 | |
Interview with Laura A. Bolte, MSc, Geke A. P. Hospers, MD, PhD, and Rinse K. Weersma, MD, PhD, authors of Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma. Hosted by Jack West, MD. | |||
| Adoption of Innovative Therapies Across Oncology Practices | 05 Jan 2023 | 00:21:08 | |
Interview with Nancy L. Keating, MD, MPH, author of Adoption of Innovative Therapies Across Oncology Practices—Evidence From Immunotherapy. Hosted by Jack West, MD. | |||
| Adjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy | 08 Dec 2022 | 00:18:37 | |
Interview with Marco Del Chiaro, MD, PhD, author of Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. Hosted by Jack West, MD. | |||
| Association of DCVax-L With Extension of Survival Among Patients With Glioblastoma | 17 Nov 2022 | 00:18:28 | |
Interview with Linda M. Liau, MD, PhD, author of Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. Hosted by Jack West, MD. | |||
| Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma | 27 Oct 2022 | 00:12:16 | |
Interview with Olivier J. van Not, MD, and Karijn P. M. Suijkerbuijk, MD, PhD, authors of Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. Hosted by Jack West, MD. | |||
| Prostate-Specific Antigen Screening Rates and Metastatic Prostate Cancer Incidence in the VHA | 24 Oct 2022 | 00:16:36 | |
Interview with Brent S. Rose, MD, author of Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities. Hosted by Jack West, MD. | |||
| Therapy and Survival Patterns in Patients With Stage 2/3 Rectal Cancer Treated With Trimodality Therapy | 18 Aug 2022 | 00:15:26 | |
Interview with Hagen F. Kennecke, MD, author of Patterns of Practice and Improvements in Survival Among Patients With Stage 2/3 Rectal Cancer Treated With Trimodality Therapy. Hosted by Jack West, MD. | |||
| Global Association of COVID-19 Pandemic Measures With Cancer Screening | 07 Jul 2022 | 00:12:53 | |
Interview with Paolo Boffetta, MD, author of Global Association of COVID-19 Pandemic Measures With Cancer Screening: A Systematic Review and Meta-analysis. Hosted by Jack West, MD. | |||
| A Conversation With Dr Kirsten Bibbins-Domingo, JAMA's New Editor in Chief | 05 Jul 2022 | 00:22:07 | |
In July 2022, Kirsten Bibbins-Domingo, PhD, MD, MAS, took on a new role as the 17th editor in chief of JAMA and the JAMA Network. In conversation with Nobel laureate Harold Varmus, MD, Bibbins-Domingo discusses her research background, approaches to leadership in health care, and the critical role that journals play in communication about public health and science. | |||
| High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade | 16 Jun 2022 | 00:19:09 | |
Interview with Mark M. Awad, MD, PhD, author of Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. Hosted by Jack West, MD. | |||
| Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality | 19 May 2022 | 00:14:06 | |
Interview with Lars Björnebo, MSc, and Anna Lantz, MD, PhD, authors of Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality. Hosted by Jack West, MD. | |||
| Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | 28 Apr 2022 | 00:23:31 | |
Interview with David Anthony Palma, MD, PhD, and Anthony C. Nichols, MD, authors of Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial Hosted by Jack West, MD. | |||
| Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer | 17 Mar 2022 | 00:20:09 | |
Interview with Kenneth L. Kehl, MD, MPH, author of Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). Hosted by Jack West, MD. | |||
| Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer | 17 Feb 2022 | 00:15:22 | |
Interview with Ruth C. Carlos, MD and Gelareh Sadigh, MD, authors of Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial. Hosted by Jack West, MD. | |||
| Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy | 20 Jan 2022 | 00:18:16 | |
Interview with Laurent Dercle, MD, PhD, author of Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis. Hosted by Jack West, MD. | |||
| Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma | 23 Dec 2021 | 00:22:38 | |
Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD. | |||
| Chemoradiotherapy Plus Induction or Consolidation Chemotherapy for Locally Advanced Rectal Cancer | 18 Nov 2021 | 00:23:56 | |
Interview with Emmanouil Fokas, MD, DPhil, author of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. Hosted by Jack West, MD. | |||
| Clinical Outcomes and Toxic Effects of Single-Agent ICI Treatment Among Geriatric Patients With Cancer | 04 Nov 2021 | 00:21:19 | |
Interview with Abdul Rafeh Naqash, MD, and Caroline A. Nebhan, MD, PhD, authors of Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. Hosted by Jack West, MD. | |||
| Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer | 16 Sep 2021 | 00:34:49 | |
Interview with Laura J. Esserman, MD, and W. Fraser Symmans, MD, authors of Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial | |||
| Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With NSCLC | 12 Aug 2021 | 00:16:52 | |
Interview with Puneeth Iyengar, MD, PhD, author of Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non–Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial | |||
| Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer | 01 Jul 2021 | 00:16:31 | |
Interview with Carsten Finke, MD, and Frederik Bartels, MD, authors of Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer | |||